Immunosenescence (the aging immune system)
Your immune system ages on its own schedule: the thymus that trains new immune cells gives way to fat, the cells that hunt infections and cancers kill less well, and worn-out cells pile up. The one countermeasure with solid trial evidence is vaccines that work in older adults; exercise is the most plausible lifestyle lever, and the immune-signal drugs and "immune-boosting" supplements in the headlines are unproven for healthy people.
Take the vaccines shown to work in older adults: the higher-dose flu vaccine made for people over 65, the newer RSV vaccine (tested in people over 60) and the recombinant shingles vaccine. Keep exercising, avoid obesity and sleep enough, which is worth doing anyway even though the immune-specific evidence is thin. Skip immune-boosting supplements, IL-15 products and anything sold as thymus regeneration.
What goes wrong as the immune system ages
Immunosenescence is the age-related remodelling and decline of the immune system. It is not one of the twelve hallmarks of aging, but it sits alongside their integrative tier: less a single root cause than a system-wide failure that both results from upstream damage and then accelerates it.[1] The decline itself is well established; three parts of it matter most.
The thymus runs down. This organ behind the breastbone schools fresh T-cells, the white blood cells that recognise specific threats. Its working tissue dwindles from the first year of life and gives way to fat from the teenage years on.[2] Its output of new T-cells falls but does not stop, and continues well into late adulthood.[3] As fewer new cells arrive, the immune system leans on its existing memory cells and is slower to recognise threats it hasn't seen before, which is part of why vaccines work less well and new infections hit harder with age.[4] The adult thymus still matters: in an observational study, adults who had it removed during heart or chest surgery had more deaths and cancers over the next five years than similar patients who kept it.[5]
T-cells wear out. Late-stage T-cells pick up the surface markers of senescence and divide poorly when they meet their target; rather than falling idle, many switch to a cruder style of killing that resembles natural killer cells.[6]
Natural killer cells lose their edge. Natural killer (NK) cells are the body's first responders against virus-infected and pre-cancerous cells. Each one kills less well with age, even though their number often holds steady or rises.[7] In a Japanese community study of adults mostly over 40, people with low NK activity developed more cancer over 11 years,[8] and in nursing-home residents with poor physical function, low NK activity went with more infections and more deaths from infection.[9] Both are single observational studies.
The net effect is an immune system that is less protective and more inflammatory at the same time: the immune contribution to the chronic, low-grade inflammation of older bodies covered under chronic inflammation.
IL-15: the signal that keeps the hunters alive
Much of this story can be told through one immune signalling molecule, interleukin-15 (IL-15). It is the main survival and growth signal for exactly the cells that fare worst with age: memory CD8⁺ T-cells (a "killer" T-cell type) and NK cells.[10] The receptor biology is well established; treating IL-15 as the thread that ties immune aging together is a useful lens rather than a settled fact, and most of the evidence behind it comes from cells and animals.
IL-15 is unusual in how it is delivered. Rather than floating freely in the blood, it is mostly handed over cell to cell: a producing cell holds it on its surface and presents it to a neighbour, which keeps so potent a signal local and tightly controlled.[11]
In the lab, IL-15 pushes against T-cell aging. In memory CD8⁺ T-cells grown in culture, it keeps the telomere-repairing enzyme telomerase active and minimises the loss of chromosome caps across repeated divisions (see telomere attrition).[12] In human tumour-fighting T-cells grown with IL-15 instead of the related signal IL-2, senescence was delayed, and those cells held back tumours better after transfer into mice.[13] But IL-15 also helps the worn-out T-cells described above to expand,[14] an early sign that more is not simply better.
Clearing senescent cells. A young immune system finds and kills senescent cells, the damaged cells that stop dividing and leak inflammatory signals. In mice, disabling the killing machinery of NK cells and killer T-cells lets senescent cells pile up, drives chronic inflammation and shortens life.[15] IL-15 probably supports this clean-up, since it keeps those cells alive, but no study has shown that directly, and none in people. The targets also fight back: in lab and animal studies, senescent cells secrete a signal that blunts NK-cell recognition and shed decoy molecules that soak up NK receptors, much as tumours do.[16] That is part of why simply "boosting" immunity is harder than it sounds. The senescent cell's side of the story is on cellular senescence.
Why more IL-15 is not better
The single most useful idea here is that IL-15 works in pulses. When human NK cells are bathed in IL-15 continuously in the lab, they first ramp up, then suffer a metabolic collapse and lose their ability to kill; giving them a break of a few days between exposures prevented it. Exhausted cells also controlled tumours poorly once transferred into mice.[17] That is why continuous IL-15 drug dosing is the worry. Whether the raised IL-15 reported in obesity or persistent infection does the same thing in people has not been tested.
Too much IL-15 can also cause disease. Chronically high local IL-15 drives autoimmune disease, most clearly celiac disease, where gluten-triggered IL-15 in the gut lining breaks immune tolerance and destroys the intestinal surface.[18]
The body's own way of producing pulses is muscular work: contracting muscle releases IL-15 as a "myokine", under the control of the cell's energy sensor.[19] In people, a meta-analysis of 15 studies found that a single session of endurance or strength exercise raises blood IL-15 for a short time, while weeks to months of training leave resting levels with no clear change.[20] A larger 2024 analysis was less clear-cut: the average rise was similar in size but not statistically reliable, with signs that small positive studies were over-represented.[21] That fits the pulse idea, as a fit rather than a demonstration, and it echoes the muscle-derived "IL-6 paradox" described under chronic inflammation.
What the centenarians show, and what they don't
People who reach extreme old age are a tempting natural experiment, but every study here is a small one-time snapshot of people who already aged well, so none can say what caused it.
In 30 people aged over 95, most of them women, blood IL-15 was higher than in adults under 60 or people aged 60 to 89.[22] A 2024 study of 40 fairly healthy, independent people aged 90 and over in Kazakhstan also found higher IL-15 than in adults aged 46 to 60, though several other inflammatory signals were raised too.[23] That stands out because ordinary aging seems to go the other way: pooling 59 studies of healthy adults, people over 65 typically have lower IL-15 than younger adults, except overweight older adults, whose levels are higher.[24]
The T-cells of high-performing centenarians multiplied more when stimulated and carried longer telomeres and more telomerase activity than those of low-performing centenarians or people aged 67 to 83. Low performers looked like the younger controls, so this is a property of aging well, not of reaching 100.[25]
The usual explanation, that centenarians pair strong immune activity with a stronger brake, rests on thinner evidence than it sounds. In a Chinese study, centenarians did not carry more of the regulatory T-cells that restrain inflammation than younger adults. What differed was the balance between inflammatory and regulatory T-cells, which had tipped back toward the regulatory side, and higher blood levels of the anti-inflammatory signal IL-10; the detailed cell tests involved just 8 people per group.[26] An Italian survey of 22 centenarians found no general rise in anti-inflammatory signals.[27] Exceptional immune aging may look less like suppressing the immune system than like pairing active surveillance with well-tuned restraint, but that is a hypothesis.
Vaccines: the lever with trial evidence
Because the aging immune system responds less to vaccines, some vaccines are built to work around it, and these are the one countermeasure backed by randomised trials.
Higher-dose flu vaccine. Developed for people over 65. Across 14 trials in more than half a million older adults, it cut flu hospitalisations by about 40% compared with the standard dose, about 4 fewer per 10,000 people vaccinated, with no clear effect on deaths. The authors call the absolute benefit modest,[28] and the largest single trial missed its broader goal of fewer flu-or-pneumonia hospitalisations, though flu hospitalisations alone were lower.[29]
RSV vaccine. A newer vaccine against respiratory syncytial virus (RSV) cut RSV hospitalisations in people over 60 by more than 80% in a large, open-label, manufacturer-funded Danish trial. The numbers were small: 3 versus 18 cases among about 65,000 people in each group.[30]
Shingles vaccine. The recombinant shingles vaccine contains an immune-boosting ingredient called an adjuvant and prevented about 90% of shingles even in people over 80, at the cost of sore arms and short-lived flu-like reactions in most recipients.[31] Its possible effect on dementia is covered on the shingles vaccine page.
Exercise, weight and sleep: plausible, thinly tested
These are worth doing for many other reasons. The question here is narrower: do they slow immune aging? The honest answer is that nobody has shown it.
Exercise is the most plausible lever. Whether harder sessions raise IL-15 more has never been tested, and whether the post-exercise rise actually sharpens NK or T-cells in people is inferred from lab work.[32] The best human study is a snapshot: people aged 55 to 79 who had cycled seriously for most of their adult lives had more fresh T-cells leaving the thymus than inactive people their age, yet just as many worn-out T-cells.[33] Small, bias-prone studies hint that active people respond somewhat better to one flu-vaccine strain.[34] A 2026 review of reviews rated the certainty of every exercise effect on immune-aging blood markers as very low; no trial has shown that exercise slows immune aging.[35] The wider case for strength work is on resistance training.
Weight and diet. The direct evidence is animal. In aging rats, IL-15 signalling became chronically over-expressed in fat tissue and, together with another inflammatory signal, degraded insulin signalling, and lifelong calorie restriction prevented it, but that was 40% restriction in 36 animals, far beyond anything this site suggests.[36] As with inflammation generally, much of the benefit probably rides on avoiding excess fat and eating well, not on any schedule trick. One small finding in 61 amateur runners linked under 45% of energy from carbohydrate with lower IL-15; it is a single observation, not a reason to change your diet.[37]
Sleep. The most direct human evidence concerns vaccines: in pooled studies of healthy adults, people whose sleep was measured objectively and who slept too little around a vaccination made noticeably fewer antibodies. Those studies only included adults aged 18 to 60, the effect was clear in men but not statistically significant in women, and self-reported short sleep (under 6 hours) showed no clear effect.[38]
The drug and supplement frontier
None of this is established for healthy adults, and much of it is a real caution.
N-803, the IL-15 superagonist. This engineered drug delivers a strong, long-lasting IL-15 signal. It is now approved in the US, as Anktiva, for one hard-to-treat form of bladder cancer, given into the bladder together with BCG, the standard bladder-cancer treatment; in the uncontrolled, company-funded trial behind the approval, the cancer cleared in about six in ten patients.[39][40] Because it goes into the bladder, that record says little about IL-15 in the bloodstream. In two early cancer trials it caused no dose-limiting toxicity, though fever and chills after drip doses, an injection-site rash in almost everyone dosed under the skin, and transient high blood pressure at the highest doses were common.[41][42] The serious harms belong to plain IL-15 given daily into a vein: in its first trial in 18 cancer patients, severe drops in blood pressure, falling platelets and liver-enzyme rises forced a tenfold dose cut.[43] These are cancer drugs used under close monitoring; no trial has tested raising IL-15 in healthy people. The broader class of unproven anti-aging drugs is covered under geroprotectors.
Engineered NK-cell therapies. NK cells engineered to make their own IL-15, combined with a cancer-targeting receptor, have been given to patients with B-cell lymphomas and leukaemia in small early-phase trials: 8 of 11 responded in the first report and about half of 37 once the trial was expanded, with no cytokine-release syndrome, nerve toxicity or graft-versus-host disease reported.[44][45] Nothing like them has been tried for aging.
"Exercise mimetic" supplements. Beta-alanine, the plant compound eugenol and multi-ingredient mitochondrial cocktails are promoted on the strength of IL-15. The beta-alanine evidence is one small trial in 22 young male volleyball players, in a journal not indexed in PubMed, which found higher blood IL-15 but measured no immune outcome.[46] Eugenol's case is mouse and cell work only.[47] A 12-ingredient mix tested in skin cells from older women did not raise IL-15 at all, and the study was funded by a company that holds an IL-15 patent, has a stake in a product containing the same ingredients, and whose chief executive is an author.[48] None has shown an immune or longevity benefit in a healthy person.
Thymus "regeneration." An often-cited regimen of growth hormone, DHEA (dehydroepiandrosterone, a hormone supplement) and metformin rests on one uncontrolled pilot in 9 men, run by a company with a related patent,[49] and its controlled follow-up has posted no results; treat it as unproven.[50]
Can you measure your immune age?
Not usefully, yet. Researchers have built immune-age scores from blood, and a thymus score read from routine chest scans, and each is linked to mortality in large cohorts.[51][52][53] Two developers of one blood score, iAge, co-founded a company that uses it. These are research tools: none can yet tell you whether a change you make is working.
Further reading
- Goyani P, et al. Immunosenescence: Aging and Immune System Decline. Vaccines (Basel) 2024.[54]
- Mishra A, Sullivan L, Caligiuri MA. Molecular pathways: interleukin-15 signaling in health and in cancer. Clin Cancer Res 2014.[55]
- Felices M, et al. Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight 2018.[56]
- Khalafi M, et al. Interleukin-15 responses to acute and chronic exercise in adults: a systematic review and meta-analysis. Front Immunol 2023.[57]
- Bettariga F, et al. Exercise training mode effects on myokine expression in healthy adults: A systematic review with meta-analysis. J Sport Health Sci 2024.[58]
- Zhou L, et al. Centenarians Alleviate Inflammaging by Changing the Ratio and Secretory Phenotypes of T Helper 17 and Regulatory T Cells. Front Pharmacol 2022.[59]
- Pinti M, et al. A Comprehensive Analysis of Cytokine Network in Centenarians. Int J Mol Sci 2023.[60]
- Zhao W, et al. Effect of high-dose versus standard-dose influenza vaccines on hospitalisation outcomes and mortality in older adults: a systematic review and meta-analysis. Lancet Healthy Longev 2026.[61]
- Lassen MCH, et al. RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults. N Engl J Med 2026.[62]
- Cunningham AL, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med 2016.[63]
- Duggal NA, et al. Major features of immunesenescence, including reduced thymic output, are ameliorated by high levels of physical activity in adulthood. Aging Cell 2018.[64]
- Chai G, Xue J, Xie B. Effects of exercise and physical activity on circulating inflammaging- and immunosenescence-related biomarkers in older adults and adults with chronic diseases: an umbrella review. Front Immunol 2026.[65]
- Conlon KC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 2015 — n=18; the trial where dose-limiting toxicity was observed.[66]
- Imai K, et al. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000.[67]